Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SnRNA-seq and genome-wide CRISPR screening define the complete transcriptional trajectory and functional drivers of podocyte stress.

Cellular and molecular life sciences : CMLS·2026

Same author

Trial End Points in ANCA-Associated Vasculitis: Are We Missing the Boat?

Journal of the American Society of Nephrology : JASN·2026

Same author

Development and validation of EULAR quality indicators for lupus nephritis: adherence trends and impact on clinical outcomes.

Annals of the rheumatic diseases·2026

Same author

PREVENT Equations: Implications for Stroke Prevention.

Stroke·2026

Same author

Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Same author

Inotodiol ameliorates oxidative stress and apoptosis by regulating PI3K/Akt/GSK-3β signaling pathways in diabetic nephropathy.

Renal failure·2026

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Risk factor obesity: Treatment Standard.

Mahtab Mashayekhi¹, Jianbo Qing², Giv Heidari-Bateni³

¹Division of Nephrology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association

|July 14, 2026

Summary

Obesity is a major risk factor for chronic kidney disease (CKD) through metabolic and inflammatory pathways. Emerging treatments, like incretin-based therapies, offer new hope for managing obesity-related kidney injury and reducing cardiovascular risks.

Keywords:

GLP-1RA gut-microbiota kidney disease obesity

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Area of Science:

Nephrology
Endocrinology
Public Health

Background:

Obesity is a global epidemic linked to chronic kidney disease (CKD) beyond diabetes and hypertension.
Excess adiposity drives kidney injury via hemodynamic, metabolic, and inflammatory pathways.
Rising obesity rates necessitate understanding its role in CKD pathogenesis.

Purpose of the Study:

Review current standards for managing obesity as a CKD risk factor.
Discuss novel developments in pathophysiology, diagnosis, and outcome prediction.
Explore emerging treatments, including incretin-based therapies, for obesity-related kidney disease.

Main Methods:

Literature review of current treatment standards.
Analysis of emerging research on pathophysiology and diagnosis.
Discussion of novel therapeutic strategies.

Main Results:

Obesity independently contributes to kidney injury through multiple mechanisms.
Incretin-based therapies show promise in managing obesity-related kidney disease.
Early diagnosis and risk stratification are crucial for patient outcomes.

Conclusions:

Obesity is a critical, independent risk factor for CKD.
Novel therapies are needed to address the growing burden of obesity-related kidney disease.
Integrated management strategies are essential to reduce morbidity and mortality.